Back to the main directory
EarningsReview / Equity
- Lundbergs (Sell, TP: SEK415.00) - Winner on real estate windfall by DnB Markets
- Recipharm (No_rec, TP: SEK) - Strong finish to the year by DnB Markets
- Catena (Sell, TP: SEK350.00) - Banking as a side business? by DnB Markets
- Alimak (Buy, TP: SEK145.00) - On the right (but bumpy) track by DnB Markets
- Seafood - Fat Trout Weekly by DnB Markets
- Soft NCS liquids production again by DnB Markets
- Rameda (RMDA EY) by HSBC
- Ambuja Cements (ACEM IN) by HSBC
- Sustainable upgrades, but still risks in Sports Betting by BNP Paribas
- As the dust settles by BNP Paribas
- Vale (VALE US) by HSBC
- Alimak Group - Weak finish to 2019 by Danske Bank Equity Research
- Recipharm - Rights issue overshadowing operational performance by Danske Bank Equity Research
- (17– 21 February 2020) by Oddo BHF
- 4Q19 results and questions for management by BNP Paribas
- ALMIRALL: RDOS. 2019 (ANÃLISIS BANCO SABADELL) by Sabadell
- INVEST SECURITIES - Ediliziacrobatica : S2 2019 moins flamboyant que le S1 - ACHAT, OC 9,2€ by Invest Securities
- In Need Of Cyclical Support by BNP Paribas
- Reduce and reuse by BNP Paribas
- CLP Holdings Ltd (2 HK) by HSBC
- Buyback and outlook reassure by BNP Paribas
- SAS (Hold, TP: SEK14.50) - Soft Q1e with coronavirus in focus by DnB Markets
- Otello (Buy, TP: NOK26.00) - Q4 likely another proof point by DnB Markets
- Oncopeptides (Buy, TP: SEK240.00) - A busy year ahead by DnB Markets
- Nine Dragons Paper (2689 HK) by HSBC